<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02990611</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-654</org_study_id>
    <nct_id>NCT02990611</nct_id>
  </id_info>
  <brief_title>Real-Life Efficacy and Safety of Nivolumab Monotherapy or in Combination With Ipilimumab in Patients With Advanced (Unresectable or Metastatic) Melanoma</brief_title>
  <acronym>NICO</acronym>
  <official_title>A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) Monotherapy or In Combination With Ipilimumab In Patients With Advanced (Unresectable or Metastatic) Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Real-Life Efficacy and Safety of Nivolumab monotherapy or in combination with Ipilimumab in
      Patients with Advanced (Unresectable or Metastatic) Melanoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS) of nivolumab/ipilimumab combination therapy</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) of nivolumab monotherapy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response Rate (BORR)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Gender in adult patients with advanced Melanoma initiating nivolumab monotherapy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Height in adult patients with advanced Melanoma initiating nivolumab monotherapy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Weight in adult patients with advanced Melanoma initiating nivolumab monotherapy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Age in adult patients with advanced Melanoma initiating nivolumab monotherapy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Gender in adult patients with advanced Melanoma initiating nivolumab/ipilimumab combination therapy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Height in adult patients with advanced Melanoma initiating nivolumab/ipilimumab combination therapy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Weight in adult patients with advanced Melanoma initiating nivolumab/ipilimumab combination therapy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Age in adult patients with advanced Melanoma initiating nivolumab/ipilimumab combination therapy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Initial Diagnosis of Melanoma in adult patients with advanced Melanoma initiating nivolumab monotherapy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Histological Subtypes in adult patients with advanced Melanoma initiating nivolumab monotherapy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Performance Status in adult patients with advanced Melanoma initiating nivolumab monotherapy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Comorbidities in adult patients with advanced Melanoma initiating nivolumab monotherapy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of History of Cancer in adult patients with advanced Melanoma initiating nivolumab monotherapy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Initial Diagnosis of Melanoma in adult patients with advanced Melanoma initiating nivolumab/ipilimumab combination therapy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Histological Subtypes in adult patients with advanced Melanoma initiating nivolumab/ipilimumab combination therapy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Performance Status in adult patients with advanced Melanoma initiating nivolumab/ipilimumab combination therapy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Comorbidities in adult patients with advanced Melanoma initiating nivolumab/ipilimumab combination therapy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of History of Cancer in adult patients with advanced Melanoma initiating nivolumab/ipilimumab combination therapy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of variation in treatment patterns in adult patients diagnosed with advanced melanoma</measure>
    <time_frame>5 years</time_frame>
    <description>overall dosing, regimen, indication, treatment, rationales, management and characteristics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of incidence of Adverse Events (AEs)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of severity of Adverse Events (AEs)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of management of Adverse Events (AEs)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ C-30)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Nivolumab Monotherapy patients</arm_group_label>
    <description>Patients who start treatment with nivolumab monotherapy for the first time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab/Ipilimumab Combination therapy patients</arm_group_label>
    <description>Patients who start treatment with the combination therapy of nivolumab with ipilimumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non Interventional</intervention_name>
    <arm_group_label>Nivolumab Monotherapy patients</arm_group_label>
    <arm_group_label>Nivolumab/Ipilimumab Combination therapy patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Data of patients will be collected who are treated in office-based practices and
        outpatients dept. of clinics across Germany
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â‰¥ 18 years

          -  advanced melanoma (Stage III/Stage IV)

          -  histologically confirmed diagnosis

          -  treatment decision for nivolumab mono- or combination therapy already taken

          -  signed informed consent

        Exclusion Criteria:

          -  current primary diagnosis of a cancer other than advanced melanoma, that requires
             systemic or other treatment

          -  previous treatment with nivolumab

          -  current active participation in an interventional clinical trial for treatment of
             advanced melanoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2016</study_first_submitted>
  <study_first_submitted_qc>December 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2016</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

